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Microcystin-LR (MCLR) is a cyanobacterial toxin known for its acute hepatotoxicity. Despite being recognized as tumour promoter,
its genotoxicity is far from being completely clarified, particularly in organs other than liver. In this work, we used the comet and/or
the micronucleus (MN) assays to study the genotoxicity of MCLR in kidney- (Vero-E6) and liver-derived (HepG2) cell lines and in
blood cells fromMCLR-exposedmice. MCLR treatment (5 and 20 𝜇M) caused a significant induction in theMN frequency in both
cell lines and, interestingly, a similar positive effect was observed in mouse reticulocytes (37.5𝜇gMCLR/kg, i.p. route). Moreover,
the FISH-based analysis of the MN content (HepG2 cells) suggested that MCLR induces both chromosome breaks and loss. On
the other hand, the comet assay results were negative in Vero-E6 cells and in mouse leukocytes, with the exception of a transient
increase in the level of DNA damage 30 minutes after mice exposure. Overall, the present findings contributed to increase the
weight of evidence in favour of MCLR genotoxicity, based on its capacity to induce permanent genetic damage either in vitro or in
vivo. Moreover, they suggest a clastogenic and aneugenic mode of action that might underlie a carcinogenic effect.
1. Introduction
Microcystins are secondary metabolites of cyanobacteria
occurring worldwide in freshwater resources and have been
associated with episodes of human and animal acute liver
toxicity [1, 2]. The liver specificity of microcystins has been
attributed to the selective expression by hepatocytes of a
family ofmembrane transporters, the organic anion polypep-
tide transporter (OATP) [3, 4], through which microcystins
enter into the cells. The mechanism of acute hepatotoxi-
city is believed to be mediated by the inhibition of ser-
ine/threonine protein phosphatases 1 and 2A (PP1 and PP2A)
[5] and the consequent induction of cytoskeletal proteins
hyperphosphorylation leading to hepatocyte deformation,
collapse of tissue organization, and necrosis [6]. Increasing
evidences have demonstrated that microcystins might also
target other organs such as kidney [7–9], intestine [10, 11],
lungs [12], reproductive system [13], and brain [14], although
the knowledge about its toxicity on these organs is very
restricted. The establishment of a guideline for microcystins
in drinking water [15] and the implementation of water
quality surveillance programs have contributed to a decrease
in the risk of acute intoxication by waterborne cyanotoxins
[16].
However, microcystins are classified by the International
Agency for Research on Cancer as possibly carcinogenic to
humans [17]. Epidemiological studies have suggested an asso-
ciation between chronic exposure to low doses of these toxins
through drinking water and an increase in primary hepa-
tocellular [18, 19] and colorectal cancers [20]. Furthermore,
two-stage rodent carcinogenesis assays have demonstrated
thatmicrocystin-LR (MCLR), themost abundant and studied
microcystin variant, is involved in tumour promotion [21–
23] while several in vivo and in vitro studies have pointed to
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a genotoxic activity of MCLR (revised in [24]), although this
issue is not consensual.
Several reports have shown that MCLR induces DNA
damage in liver cells in vivo [10, 25, 26] and in distinct cells
types in vitro [25, 27–34], but the mechanism behind the
observed DNA breakage is not clear and seems to be dose-
dependent and cell-type dependent. To our knowledge, no
MCLR-DNA adduct has been identified so far, suggesting
an indirect mechanism for its genotoxicity. In fact, oxidative
stress was proposed as a mechanism of MCLR-induced
DNA damage [29–33]. Supporting this hypothesis, studies
on liver cells have demonstrated that subcytotoxic doses
of MCLR induce the formation of 8-oxo-deoxyguanosine
(8-oxo-dG), a marker of oxidative DNA damage [35, 36].
On the contrary, some authors have attributed the MCLR-
induced DNA lesions, measured by the comet assay, to
endonucleolytic DNA degradation associated with apoptosis
[27] or necrosis [25] rather than to genotoxic events. A
permanent chromosome damaging effect has been addition-
ally suggested for microcystins by studies that showed an
induction of micronuclei (MN) in vivo [28] or in vitro [37].
In contrast, other authors reported no effect of MCLR on
the micronucleus frequency in different cell models [38–41],
in agreement with the negative results of the chromosome
aberrations analysis [27, 42].
The controversy concerningMCLRgenotoxicity probably
arises from the analysis of distinct endpoints in different
in vivo and in vitro biological models exposed to distinct
microcystins sources (pure toxin or cyanobacterial extracts),
hampering the establishment of a definitive conclusion about
MCLR genotoxicity (reviewed in [24]).
Despite its toxicity, recent studies have suggested that
MCLR might be exploited to be used as an anticancer
agent [43, 44]. This possibility arises from the observation
that some tumours overexpress OATPs comparatively to
the corresponding normal tissues [44] and that MCLR, at
subnanomolar concentrations, is a potent cytotoxic agent
against OATP-transfected tumour cells [43].
Considering this risk/benefit duality of MCLR, the char-
acterization of its genotoxicity has a twofold goal: either
to evaluate the potential health hazard from continuous
exposure to low doses from environmental sources or to
evaluate the safety of MCLR considering their potential
pharmacological applications.
The present study was aimed at contributing to the
genotoxicity evaluation ofMCLR in vitro, in twomammalian
cell lines representative of liver and kidney (HepG2 and
Vero-E6 cell lines, resp.) and in vivo in C57Bl/6 mice. In
order to obtain the maximum information about MCLR
genotoxicity from these experimental models, a combination
of the micronucleus and the comet assays was selected. Such
a combination covers different genetic endpoints, given that
the DNA strand breaks and alkali-labile sitesmeasured by the
comet assay are primary DNA lesions with relevance for gene
and chromosome mutation formation whereas micronuclei
reflect chromosome abnormalities due to clastogenic and/or
aneugenic events [45–47]. Moreover, gene mutations and
numerical/structural chromosome changes are relevant for
carcinogenesis and the cytokinesis-block micronucleus assay
has been shown to have a predictive value for cancer risk [48].
In order to add some insights intoMCLR’smode of action, we
evaluatedmicronucleus content using the fluorescence in situ
hybridization (FISH) coupled to the micronucleus assay.
2. Materials and Methods
2.1. Genotoxicity Assays in Vero-E6 and HepG2 Cell Lines
2.1.1. Cell Lines and Reagents. The Vero-E6 (African green
monkey, Cercopithecus aethiops, kidney epithelial cells)
and HepG2 (human hepatocellular carcinoma) cell lines
were obtained from the American Type Culture Collection
(ATCC-CRL 1586) and German Collection of Microorgan-
isms and Cell Cultures (DSMZ ACC 180), respectively. Vero-
E6 cells were grown in Modified Eagle Medium (MEM)
supplemented with 10% fetal bovine serum (FBS), 0.1mM
nonessential amino acids, and 1mM sodium pyruvate.
HepG2 cells were grown in RPMI 1640 w/Glutamax, con-
taining 15% FBS. Both cell lines were maintained at 37∘C,
in a 5% CO
2
humidified incubator. All culture media and
supplements were purchased fromGibco-Invitrogen (Paisley,
UK).
Microcystin-LR (CAS Number 101043-37-2) was pur-
chased from Alexis/Enzo Life Sciences (Lausen, Switzerland)
as a white solid film (purity ≥ 95%, by HPLC). A stock
solution of MCLR (1mM) was prepared by dissolving the
toxin in cell culture medium or saline solution and kept at
−20∘C until use. Work solutions of 5 and 20 𝜇M of MCLR
were prepared immediately before testing, by diluting the
stock solution in cell culture medium or saline solution.
2.1.2. Cytotoxicity (Neutral Red) Assay. The neutral red (NR)
assay [49] was used to evaluate the cell lines viability after
exposure to MCLR. This assay was conducted in 96-well
plates containing 1 × 104 viable cells/100 𝜇L of growth
medium. Cells were exposed to 5 and 20 𝜇M of MCLR
during 24 h. H
2
O
2
(400mM, 1 h) was included as positive
control and untreated cells were the negative control. Three
replicates were performed per treatment condition. After
treatment, the exposure medium was replaced by fresh
culturemedium containing aNR solution (50 𝜇g/mL; Merck,
Darmstadt, Germany) and incubated for 3 h. Cells were
rinsed with PBS and the incorporated NR was extracted with
an ethanol : acetic acid : water (50 : 1 : 49) solution. NR incor-
poration was quantified spectrophotometrically at 540 nm
using a Multiscan Ascent spectrophotometer (Labsystems,
Helsinki, Finland).
The relative cell viability, expressed as the percentage of
viable cells, was estimated as the ratio between the mean
absorbance of treated and control cells, assuming the mean
absorbance of the negative control to represent 100% viable
cells. The results are expressed as the mean value (±SE) of
three independent experiments per treatment condition.
2.1.3. Comet Assay. Vero-E6 cells were plated in 24-well
plates, at a density of 5 × 104 cells per well, and incubated
at 37∘C for 24 h to allow for cells adherence and growth.
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After 24 h, the culturemediumwas replaced by freshmedium
containing 5, 10, and 20 𝜇M of MCLR. Cells were exposed,
in duplicate cultures, for short (4 h) and long (24 h) periods.
Simultaneously, positive (H
2
O
2
, 100 𝜇M for 30min at the
end of the exposure period) and negative (nontreated cells)
controls were included. The comet assay was performed
according to Pinto et al. [50]. Briefly, following exposure
5 × 10
4 cells were mixed with 80𝜇L of 1% low melting point
agarose to prepare 2 gels on microscope slides previously
covered with a 1% normal melting point agarose layer. Cells
were lysed (2.5M NaCl, 100mM EDTA, 10mM Tris, 1%
N-lauroylsarcosine, 10% DMSO and 1% Triton X-100, pH
10) for at least 1 h at 4∘C, and nucleoids were treated with
FPG (kindly provided by Dr. A. R. Collins, University of
Oslo, Norway) or buffer only (40mM HEPES, 100mM KCl,
0.5mM EDTA, BSA 0.2mg/mL, pH 8), for 30min at 37∘C.
DNA was allowed to unwind in alkaline conditions (300mM
NaOH, 1mM Na
2
EDTA⋅2H
2
O, pH > 13) for 40min before
subjecting to electrophoresis for 30min at 0.7 V/cm. Finally,
slides were rinsed with neutralization buffer (0.4M Tris-
HCL, pH 7.5) followed by dH
2
O, for 10min each, stained
with ethidium bromide (0.125𝜇g/𝜇L), and analysed using
a fluorescence microscope (Zeiss, Axioplan 2, Go¨ttingen,
Germany). Fifty randomly selected nucleoids per gel (i.e., 100
nucleoids per slide) were analysed with the Comet Imager 2.2
image analysis software (MetaSystems, GmbH, Altlussheim,
Germany). The percentage of DNA in the comet tail was
selected to measure DNA damage and the results represent
the mean (±SE) of three independent experiments.
2.1.4. Micronucleus Assay. Cells were seeded in 6-well plates
at a density of 5×104 viable cells per well. Following 24 h, the
growth medium was replaced by fresh medium containing
5 or 20𝜇M of MCLR and 1 h later cytochalasin B (6 𝜇g/mL
Sigma-Aldrich) was added. For each experiment, negative
(nontreated cells) and positive (MMC, 0.1 𝜇g/mL) controls
were included. At 24 h after treatment, cells were trypsinized
and harvested using a hypotonic treatment (0.075M KCl;
3min, at room temperature) followed by fixation with cold
fixative (acetic acid :methanol, 1 : 3) and spread onto glass
slides by cytocentrifugation (Shandon Cytospin, Themo
Scientific, MA, USA) at 1200 rpm, 5min. After being air-
dried, slide preparations were stained in 4% Giemsa (Merck,
Darmstadt, Germany) in phosphate buffer, pH 6.8, mounted
with Entellan (Merck), and analysed using a light microscope
(Zeiss, Axio Imager A2).
Three independent experiments were performed with
Vero-E6 cells and two experiments were performed with
HepG2 cells, using two replicate cultures per treatment con-
dition. A total of 1000 cytokinesis-blocked cells (binucleated
cells) per replica were scored for the presence of micronuclei
(MN), using the criteria described by Fenech et al. [51]. In
addition, the proportion of mono-, bi-, and multinucleated
cells was calculated by scoring 1000 cells per treatment
condition. The cytokinesis-block proliferation index (CBPI)
was calculated by the formula: CBPI = (𝑀1 + 2𝑀2 + 3𝑀3)/𝑁,
where𝑀1-𝑀2 represents the number of cells with 1-2 nuclei,
𝑀3 represents the number of cells with more than 2 nuclei,
and𝑁 is the total number of scored cells [52, 53].
2.1.5. Fluorescence In Situ Hybridization (FISH). To deter-
mine whether MCLR-induced MN in HepG2 cells were
originated from a clastogenic (centromere-negative, cm−)
or aneugenic (centromere-positive, cm+) mechanism, the
presence of centromeres inside the MN was investigated
by the FISH assay using a biotin-labelled human pancen-
tromeric probe (Cambio, Cambridge, UK). This analysis was
not performed with the Vero-E6 cell line because of the
unavailability of a green monkey pancentromeric probe.
HepG2 cells (treated with 20𝜇M of MCLR) previously
fixed and spread onto glass slides for micronucleus analysis
were also used for the FISH assay, performed according to
manufacturer instructions. Colcemid-treated (0.02 𝜇g/mL)
and untreated cultures were used as positive and negative
controls, respectively. Briefly, slides were washed in 2xSSC
buffer, dehydrated through ethanol series, and allowed to dry.
Cells were denaturedwith 70% formamide (in 2xSSC) at 70∘C
for 2min and dehydrated through ethanol series. Hybridiza-
tion with previously denatured DNA probe (10min, 85∘C)
was performed overnight at 40∘C in a humid chamber.
Posthybridization washes were performed with 50% for-
mamide in 2xSSC (5min, 37∘C) followed by 2xSSC (5min,
37∘C).The hybridization signals were revealed using an Avid-
Cy3 antibody (1 hour at 40∘C; Amersham, Uppsala, Sweden).
Cells were counterstained with DAPI (0.5 𝜇g/mL) and finally
mounted in Vectashield (Vector Laboratories, Burlingame,
CA, USA). Slides were analysed under a fluorescence micro-
scope (Zeiss, Axioplan 2) using filters for DAPI and Cy3 at a
magnification of 630x.The number of cm+ and cm−MNwas
scored within 1000 binucleated cells.
2.2. Genotoxicity Assays In Vivo in Mice Blood Cells
2.2.1. Animals, Toxin Administration, and Blood Sampling.
Male mice from the C57Bl/6 strain, 9-10 weeks old, weighing
approximately 20 g, were maintained, treated, and sacrificed
at theNational Institute ofHealthDr. Ricardo Jorge according
to the EuropeanUnion directives.The room temperature was
21–23∘C, the light/dark cycle was 12 h/12 h, and lab chow and
water were supplied ad libitum.
Six mice were injected intraperitoneally (i.p.) with
37.5 𝜇gMCLR/kg of body weight (bw). The toxin was diluted
from a stock solution of MCLR (1mM) prepared in saline
solution. Peripheral blood samples were collected before the
treatment (0 h) and at several timepoints after treatment
for the comet (0.5, 1, 24, and 48 h) and the micronucleus
(48 and 72 h) assays. The negative control consisted of
samples collected at 0 h, and positive control for both assays
was ethylnitrosourea (ENU, 100mg/kg bw; Sigma-Aldrich),
administered i.p.
2.2.2. Comet Assay in Mice White Blood Cells. Peripheral
blood was collected from the mouse tail using a heparinised
micropipette tip. A 5 𝜇L sample was diluted in 10 𝜇L of
cold mincing solution (20mM EDTA disodium, 10% DMSO,
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Figure 1: Viability of Vero-E6 and HepG2 cell lines exposed
to MCLR (5 and 20 𝜇M, 24 h) and assessed by the NR assay.
H
2
O
2
(400mM, 1 h) was used as a positive control. Results are
expressed as themeanpercentage of absorbance values relative to the
negative control (±SD) from three independent experiments tested
in triplicate.∗represents a statistically significant difference between
the treated and the control cells (𝑃 < 0.05).
prepared in D-PBS Mg2+/Ca2+/phenol red free). Five 𝜇L of
this solution was mixed with 75𝜇L of 0.7% lowmelting point
agarose to prepare two gels per sample on a microscope slide
previously covered with a 1% agarose layer. The comet assay
was thereafter performed as described for cell lines.
2.2.3. Micronucleus Assay in Mouse Reticulocytes. A periph-
eral blood sample collected from the mouse tail was dropped
onto glass slides precoated with acridine orange (1mg/mL)
and covered with a coverslip. Prior to analysis, slides were
maintained in a humidified chamber at 4∘C. Mice micronu-
cleated reticulocytes (MNRet) were scored in a total of
2000 reticulocytes (Ret) per animal, under fluorescence
microscopy. The percentage of Ret was also examined as a
measure of toxicity.
2.3. Statistical Analysis. Fisher’s exact test (2-tailed) was
used to determine whether MCLR induced a statistically
significant difference in the frequency of micronucleated
binucleated (MNBC) Vero-E6 and HepG2 cells as compared
with the untreated control cultures. The same test was used
to evaluate if MCLR induced a statistically significant change
in the proportion of cm+/cm− micronuclei in HepG2 cells,
compared to control cultures.
To determine whether MCLR induced a statistically
significant different frequency of MNRet in relation to the
control group, the two-tailed Student’s t-test was applied.
Nonparametric Mann-Whitney 𝑈 test was used to com-
pare the percentage of tail DNA between treated and control
mice groups, at several timepoints.
For all tests, the threshold of significance was 𝑃 < 0.05.
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Figure 2:Micronucleus in cytokinesis-blockedVero-E6 andHepG2
cells, following exposure to MCLR for 24 hours. Results are
expressed as the mean frequency of micronucleated binucleated
cells (MNBC) per 1000 binucleated cells (BC). Mean (±SD) were
obtained from three (Vero-E6) or two (HepG2) independent exper-
iments, using duplicate cultures. Mitomycin C (MMC, 0.1𝜇g/mL,
24 h) was used as the positive control of the assay. ∗represents a
statistically significant difference between the treated and the control
cells (𝑃 < 0.05).
3. Results
3.1. In Vitro Genotoxicity. As it is shown in Figure 1, none of
the tested MCLR concentrations interfered with the viability
of Vero-E6 and HepG2 cell lines. This confirms the absence
of cytotoxic effects in the range ofMCLR concentrations used
in the genotoxicity assays.
The data from the DNA damaging effect of MCLR in
the Vero-E6 cell line as assessed by the comet assay and
the oxidative DNA damage estimated by the FPG-modified
comet assay are presented in Table 1. None of the tested
MCLR concentrations (5, 10, and 20𝜇M) increased signifi-
cantly the level of DNA lesions in Vero-E6 cells after a 4-
or 24-hour exposure period, as compared to controls. The
genotoxicity ofMCLRwas further evaluated by theMN assay
in cytokinesis-blocked Vero-E6 and HepG2 cells (Figure 2).
In both cell lines the two tested MCLR concentrations (5 and
20𝜇M) were able to significantly increase the frequency of
MNBC, as compared to the negative control (Figure 2). Vero-
E6 cells treatment with 5𝜇MofMCLR produced a significant
1.3-fold increase in the frequency of MNBC (𝑃 = 0.012),
whereas a 1.8-fold increase was observed in treated HepG2
cells (𝑃 < 0.0001). For the highest toxin concentration a
significant 1.8-fold raise was observed for Vero-E6 cells (𝑃 <
0.0001) and a 2.1-fold raise was observed for HepG2 cells
(𝑃 < 0.0001). For each treatment condition the proportion
of mono-, bi-, and multinucleated cells was calculated to
determine the CBPI that gives an estimate of cytotoxicity.
The percentage of binucleated cells ranged between 45%–56%
and 64%–72% in Vero-E6 and HepG2 cultures, respectively,
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Figure 3: Characterization of centromere-positive (cm+) and centromere-negative (cm−) micronuclei in untreated and MCLR-treated
HepG2 cells (20𝜇M, 24 h) by FISH analysis using a human pancentromeric probe. (a) A binucleated cell with a cm+ (2 hybridization red
signals) and a cm−MN, following MCLR treatment. (b) Absolute and relative frequencies of cm+ and cm−MN per 1000 binucleated (BC)
HepG2 cells.
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Figure 4: DNA damage evaluated by the comet assay in white
blood cells from mice injected (ip) with 37.5𝜇g/kg bw of MCLR,
at several timepoints after treatment. Results are expressed as the
mean percentage of DNA in comet tails (±SD) of 6 animals per
treatment condition. The positive control, ethylnitrosourea (ENU)
(100mg/Kg), induced a 2- to 6-fold increase in the percentage of tail
DNA. ∗represents a statistically significant difference between the
treated and the control cells (𝑃 < 0.05).
and no differenceswere observed betweenMCLR-treated and
untreated cells, independently of the dose. The percentages
of binucleated cells are in agreement with values for optimal
culture conditions [52, 54].The estimatedCBPIwas 1.5-1.6 for
Vero-E6 cells and 1.6-1.7 for HepG2 cells and was not affected
by the MCLR treatment suggesting that the tested toxin
concentrations do not interfere with the normal progression
of cells through the cell cycle and confirming that they do not
affect cell viability [55].
The analysis of MN content (Figure 3) showed that the
relative proportion of cm+ and cm− MN did not differ
significantly between MCLR-treated and untreated HepG2
cells (𝑃 = 0.584), although the induction of cm− (2.6-fold)
was more pronounced than the induction of cm+ (1.6-fold)
MN.
3.2. In Vivo Genotoxicity. The results from the comet assay
in mice white blood cells (Figure 4) showed that MCLR
exposure yielded a rapid and transient 2-fold increase in
the percentage of DNA in tail, 30min after treatment (𝑃 =
0.041). At the other posttreatment timepoints, the level of
DNA damage was similar to that observed before MCLR
administration.
As for the micronuclei data, mice exposure to MCLR
caused a significant 3.9- and 2.3-fold increase in the frequency
of MNRet at 48 h (𝑃 < 0.0001) and 72 h (𝑃 = 0.003) after
treatment, respectively (Figure 5). There were no significant
differences between the percentage of Ret in MCLR-treated
and control samples.
4. Discussion
In the present work, we combined the micronucleus/FISH
and the comet assays to characterize the potential genotox-
icity of MCLR and its mechanisms on distinct in vitro and in
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Figure 5: Results of the micronucleus assay in reticulocytes (Ret)
from mice injected (i.p.) with 37.5 𝜇g/kg bw of MCLR. Results are
expressed as the mean frequency of micronucleated reticulocytes
(MNRet) (±SD) from 6 animals at several timepoints (primary
axis). The negative control consisted of samples collected at 0 h.
The positive control, ethylnitrosourea (100mg/Kg), stimulated the
increase of MNRet after 48 h (13-fold) and 72 h (2-fold) of exposure.
In the secondary axis the percentage of reticulocytes was included.
∗represents a statistically significant difference between the treated
and the control cells (𝑃 < 0.05).
vivo biological models: permanent cell lines representative of
liver and kidney and mouse blood cells.
The results from the MN assay show that noncytotoxic
concentrations (5 and 20𝜇M, 24 h) of MCLR are able to
significantly increase the frequency of MN, in both Vero-E6
and HepG2 cells, suggesting a capacity to induce permanent
chromosome damage, either chromosome fragmentation or
aneuploidy. Another study had previously reported MCLR-
induced MN in a human T-cell leukemogenic line, the TK6
cell line [37], but a similar dose-range exposure (between 1
and 40 𝜇MofMCLR) did not induceMN neither in CHO-K1
cells [38, 39] nor in human lymphocytes, although they seem
to be able to uptake the toxin [56].
In order to disclose the mechanism behind the MN for-
mation (clastogenesis or aneugenesis) the content of MCLR-
induced MN was characterized in HepG2 cells. Among the
MN detected in unexposed cells, a predominance of MN
containing whole chromosomes or centric fragments was
found with a ratio of 5 : 1 cm+ : cm− MN. The majority of
MN observed following MCLR treatment was also cm+ but
a ratio of 3 : 1 cm+ : cm− MN was determined, indicating
that MCLR induced more cm− than cm+ MN. These data
suggest that MCLR is able to act through clastogenic and
aneugenic mechanisms, with some predominance of clasto-
genesis. Given that the formation of MCLR-DNA adducts
has never been demonstrated [35] the clastogenic effect of
MCLR may be mediated by chromosome breaks indirectly
generated by oxidative DNA adducts. Even though these
have been previously reported in rat liver cells [35, 36],
Table 1: Results of DNA damage assessed by the comet assay (% of
DNA in tail) in MCLR-treated Vero-E6 cells.
MCLR (𝜇M)
% of DNA in the comet tail
Exposure time
4 h 24 h
Buffer FPG Buffer FPG
0 4.11 ± 0.21 5.13 ± 0.28 3.29 ± 0.01 3.76 ± 0.42
5 4.21 ± 0.38 4.96 ± 0.42 3.16 ± 0.39 3.37 ± 0.14
10 3.82 ± 0.04 6.41 ± 0.55 2.74 ± 0.44 4.08 ± 0.21
20 4.77 ± 0.50 5.74 ± 0.75 3.67 ± 0.16 4.22 ± 0.14
Values are themean (±SE) of three independent experiments.Thepercentage
of DNA in the comet tail induced by the positive control (H2O2, 30min) was
13.73±0.62 and 22.86±0.94, without and with FPG treatment, respectively.
we did not detect any induction of oxidative DNA damage
by the FPG-modified comet assay in MCLR-treated Vero-
E6 cells. On the other hand, it is more plausible that
MCLR can act by an aneugenic mechanism through the
indirect disturbance of the mitotic spindle, caused by its
well-documented inhibitory activity of protein phosphatases
PP1/PP2A [57, 58]. It is known that PP1/PP2A, through
their central role on phosphorylation-dephosphorylation
reactions, participate in the control of assembly and constant
turnover of microtubules [59], required for both spindle
formation and chromosome movement [60]. Disturbance
of the mitotic spindle by MCLR (≥50𝜇M) was, in fact,
demonstrated for CHO-K1 cells [61]. Additionally, its effect
on cytoskeleton components is well known [62–66] and
we have also observed MCLR-induced morphological and
ultrastructural changes (disassembly, depolymerization, and
aggregation) in microfilaments and microtubules of Vero-
E6 cells [67] at the same dose range as that found to cause
micronucleus formation in Vero-E6 and HepG2 cell lines.
The results from the comet assay show that MCLR does
not induce DNA damage in Vero-E6 cells, independently
of the timepoints tested. Furthermore, no oxidative DNA
damage was detected, as revealed by the DNA repair enzyme
FPG, which converts oxidised purines, including the major
purine oxidation product 8-oxo-dG, into single-strand breaks
(therefore detectable by the comet assay) through base exci-
sion [68]. The negative results disagree with previous reports
from Zˇegura et al. [30–32], describing a dose-dependent
and transient induction of DNA damage in MCLR-treated
HepG2 and Caco-2 cells but are in line with the negative data
reported for other cell lines (human astrocytoma IPDDC-
A2 and human B-lymphoblastoid NCNC cells) [33]. Nong
et al. [29] have also reported positive results in HepG2
cells exposed to MCLR, but for a higher toxin doserange
(30–100 𝜇M), raising the question of a possible confounding
effect from DNA degradation due to early apoptosis. A
similar conclusion came out from a study that found a
positive correlation between the frequency of apoptotic cells
and the level of DNA damage as assessed by the comet
assay, suggesting that MCLR-induced DNA damage could
be related to the early stages of apoptosis rather than to
genotoxicity [27].
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Due to the uncertainties observed in the in vitro assays,
we attempted to clarify whether mice exposure to MCLR
was able to produce DNA and chromosome damage in
peripheral blood cells. Our results from the comet assay
in leukocytes showed that MCLR (37.5𝜇gMCLR/kg bw, i.p.
route) induced a 2-fold transient increase in the level of DNA
breaks, 30min after exposure. This suggests that although
MCLR was able to induce DNA damage leukocytes might
have had the ability to rapidly repair those lesions, in
accordance with a previous report on primary cultured rat
hepatocytes [36]. In that study, MCLR (≤10 ng/mL) induced
the transient formation of 8-oxo-dG, peaking at 6 h after
treatment and then declining, suggesting a fast repair of the
DNA lesions [36]. However, two other studies reported that
microcystins failed to induce DNA damage (evaluated by the
comet assay) in rodent’s blood cells [10, 69]. For example,
in male Fisher F344 rats repeatedly exposed for 30 days to
10 𝜇gMCYR/kg bw (administered at every second day), no
effect was detected in lymphocytes and spleen cells although a
significant increase of tail DNAwas observed in liver, kidney,
and brain cells [69]. A study from Gaudin et al. [10] with
female Swiss albino mice administered at 3 and 24 h with
10–50 𝜇gMCLR/Kg bw (i.p. route) showed no induction of
DNA damage in blood cells. All these results can hardly
be compared given the differences between the exposure
conditions to microcystins and, putatively, differences in the
toxin bioavailability. However, we can hypothesize that, in
those two previous studies, a DNA damaging effect might
have occurred, although it had been repaired prior to the
genotoxicity analysis by the comet assay. Concerning theMN
assay, we observed that 48 h and 72 h following i.p. injection
of the toxin, the frequency of MNRet was significantly raised
as compared to the frequency determined before injection.
This corroborates the report of Ding et al. [28] who also
observedMN induction in reticulocytes frommale Kunming
mice injected twice (i.p., interval of 24 h) with cyanobacterial
extracts containing MCLR (0.45–45𝜇gMCLR/kg bw). Our
results confirm that MCLR is genotoxic, through its ability
to cause genetic instability in the precursors of erythrocytes
present in the bone marrow.
Taken together, both in vitro and in vivo data suggest
that the MN assay can be more sensitive than the comet
assay to reveal the genotoxicity of MCLR, which is probably
an indirect genotoxicant. Although it is far from being
consensual, this observation agrees with some studies that
compared the two methods to detect the genotoxicity of
several organic compounds in HepG2 cells [46] and of a
complex environmental mixture [50].
In summary, using kidney- and liver-derived cell lines
and blood cells from MCLR-exposed mice, we showed
that MCLR consistently induces structural and numerical
chromosome alterations, although we could not observe any
consistent increase neither in the level of DNA damage nor
in that of oxidative DNA damage, using the comet assay.
Aneuploidy induction might be a common mechanism of
MCLR genotoxicity in liver, kidney, and bone marrow cells
andmight result from its interferencewith themitotic spindle
as part of a more general effect on cell cytoskeleton, while
clastogenesis could result from an indirect mode of action.
Both chromosome breakage and chromosome loss have been
associated with cell transformation towards malignancy and
human cancer development [70] and thus can contribute to
the carcinogenic activity of MCLR.
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